Form 4: Lantern Pharma Director Granted Stock Options
Insider Transaction Report
Lantern Pharma Inc. Director Lee Troy Schalop was granted 5,000 stock options with an exercise price of $4.46, vesting over 36 months.
Summary
- Director Lee Troy Schalop of Lantern Pharma Inc. (LTRN) was granted 5,000 stock options.
- The options have an exercise price of $4.46 per share.
- The grant date for these options is August 19, 2025.
- The options were granted under the Lantern Pharma Inc. Amended and Restated 2018 Equity Incentive Plan.
- Vesting will occur in equal monthly increments over a 36-month period, commencing September 19, 2025.
- The options expire on August 18, 2035.
Sentiment
Score: 7
Explanation: The grant of stock options to a director is generally a positive sign of alignment between management and shareholder interests, reflecting a standard compensation practice.
Positives
- Granting of stock options to a director aligns management's interests with shareholder value creation.
- The options are granted under an existing equity incentive plan, indicating a structured approach to executive compensation.
Future Outlook
NA
Industry Context
This is a routine insider transaction for a biotechnology/pharmaceutical company, common for aligning director incentives.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Utilization | The stock options were granted under the Lantern Pharma Inc. Amended and Restated 2018 Equity Incentive Plan, indicating ongoing use of established corporate governance frameworks for compensation. | 08/19/2025 | Reinforces alignment of director incentives with company performance through a pre-approved plan. |
Stakeholder Impact
- Shareholders: Potential positive impact due to increased alignment of director's interests with long-term stock performance.
Next Steps
- The stock options will begin vesting in equal monthly increments starting September 19, 2025, over a 36-month period.
Key Dates
| Date | Description |
|---|---|
| 08/19/2025 | Date of earliest transaction; grant date of 5,000 stock options. |
| 08/20/2025 | Signature date of the reporting person. |
| 09/19/2025 | Commencement date for the 36-month monthly vesting period of the stock options. |
| 08/18/2035 | Expiration date of the granted stock options. |
Recommendation
holdThis Form 4 filing details a routine grant of stock options to a director as part of their compensation. While it aligns the director's interests with shareholder value, it does not provide new material information to warrant a change in investment thesis or immediate stock price movement. It's a standard operational disclosure.
Keywords
Lantern Pharma, LTRN, Stock Options, Director Compensation, SEC Form 4, Equity Incentive Plan, Insider Trading, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.